AFYX Therapeutics announced today that a study observed successful transmucosal delivery of a corticosteroid with its Rivelin patch. The Rivelin clobetasol patch (Rivelin-CLO) is a novel adhesive patch designed to deliver a therapeutic agent to wet tissue surfaces. The study, published in The European Journal of Oral Sciences, was the first to show the successful […]
Clinical Trials
Vertex Pharmaceuticals wins FDA fast track designation for its cell-based diabetes treatment
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that FDA has granted fast track designation for its VX-880, an investigational human stem cell-derived islet cell therapy for type 1 diabetes. Vertex has begun a clinical trial for VX-880 (formerly known as STx-02) in patients with type 1 diabetes (T1D) with severe hypoglycemia and impaired hypoglycemic awareness. “Ours […]
Intranasal COVID-19 vaccines could be on the horizon
All of the COVID-19 vaccines authorized to date are delivered via intramuscular injection. But the intranasal vaccines that are now in development could lead to a more diverse vaccine landscape. The company Altimmune (Gaithersburg, Md.) recently launched a Phase 1 clinical trial to test its single-dose adCOVID intranasal vaccine in 180 adult volunteers. Bharat Biotech […]
Merck moving to Phase 2 study of drug-eluting implant to prevent HIV infection
Merck (NYSE:MRK) today announced positive results from a Phase 1 study of its subdermal drug-eluting implant for preventing HIV-1 infection. The investigational implant has the potential for extended administration of islatravir for pre-exposure prophylaxis (PrEP) of HIV-1 infection, according to a news release. Islatravir is an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) being valuated […]
Pneumagen touts non-human results for intranasal drug treatment for COVID-19
Pneumagen announced today that study results show the effectiveness of its Neumifil intranasal drug in treating COVID-19. St. Andrews, Scotland-based Pneumagen’s Neumafil, a viral intranasal drug for protection against respiratory tract infections (RTIs), was used on a hamster model of COVID-19 infection and displayed effectiveness as it significantly reduced clinical signs and weight loss in […]
TerSera touts study results of infusion reaction prevention treatment
TerSera Therapeutics today announced the presentation of positive data from its study of preventing hypersensitivity infusion reactions. Deerfield, Ill.-based TerSera’s intravenous (IV) cetirizine injection was pitted against IV diphenhydramine in preventing hypersensitivity infusion reactions in patients with breast cancer and other malignancies, according to a news release. The randomized, double-blind Phase 2 study evaluated TerSera’s […]
Pulmatrix completes $40M offering, updates product pipeline timetable
Pulmatrix (NSDQ:PULM) announced today that it completed an offering with gross proceeds of approximately $40 million. Lexington, Mass.-based Pulmatrix said in a news release that it completed the registered direct offering to extend the company’s cash runway. Now, the company has additional financing to help fully fund data readouts across its development pipeline, which includes a […]
Virta Health touts study of treatment preventing progression to Type 2 diabetes
Virta Health announced today that a study of its diabetes progression prevention treatment proved more effective than initially expected. Peer-reviewed research in Nutrients highlighted the fact that only 3% of trial participants progressed to Type 2 diabetes, while over half achieved prediabetes reversal during the first two years, according to a news release. Additionally, the […]
FDA accepts New Drug Application for Eyenovia pupil dilation tech
Eyenovia (NSDQ:EYEN) announced today that the FDA accepted its New Drug Aplication for its MydCombi pupil dilation agent. MydCombi is a fixed-combination mydriatic agent for potential use in comprehensive eye exams with a formulation for touchless fixed-combination microdosing in an effort to improve the patient experience, according to a news release. New York-based Eyenovia’s proprietary Optejet […]
Inovio Pharmaceuticals posts Street-beating Q4, touts HPV trial results
Inovio Pharmaceuticals (NSDQ:INO) shares dipped after hours today after the company presented its fourth-quarter earnings and touted clinical trial results. INO shares finished the day up 4.5% at $11.60 per share but have since dropped -2.2% after hours to $11.35 per share. The Plymouth Meeting, Pa.-based company posted losses of -$24.3 million, or -14¢ per […]
